Portfolio Company RoosterBio Highlighted in Dynamk’s Recent Annual General Meeting Dynamk Capital November 1, 2021
Accelerating the Development of a Novel Cell Therapy for COVID-19–Associated Lung Fibrosis Pharma’s Almanac September 29, 2021
RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium BioInformant May 21, 2021
ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 for Rare Diseases & Cancer April 26, 2022
Univercells Technologies Partners with RoosterBio to Advance Scalable & Continuous Exosomes Manufacture January 20, 2022
RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer October 5, 2021
![$image['alt']](https://www.roosterbio.com/wp-content/uploads/2019/09/img-26.jpg)